Abcuro

Breakthrough Therapies for Autoimmune Diseases & Cancer

Home

Precision Targeting of Highly Cytotoxic T Cells in Autoimmune Disease

news

Dietmar Berger, M.D., Ph.D., Joins Abcuro Therapeutics as Board Observer

Newton, Massachusetts, June 23, 2022– Abcuro, Inc., a clinical-stage biotechnology company developing therapies for autoimmune diseases and cancer through precise modulation of cytotoxic T and NK cells, today announced that Dietmar Berger, M.D., Ph.D., currently the Chief Medical Officer and Head of Global Development at Sanofi will contribute his considerable experience to the company’s Board of

 READ MORE

READ MORE
June 23, 2022
Dietmar Berger, M.D., Ph.D., Joins Abcuro Therapeutics as Board ObserverPress Releases

Targeting Highly Cytotoxic T Cells

Highly cytotoxic T cells have been implicated as mediators of tissue damage in many autoimmune diseases

 

ABC008 in Autoimmune Disorders

ABC008, an investigational monoclonal antibody, selectively depletes highly cytotoxic T cells

 

Inclusion Body Myositis

Inclusion body myositis (IBM) is a debilitating chronic, progressive disorder in which muscle is destroyed by highly cytotoxic T cells

 

Privacy Site Credits Terms of Use

© 2022 Abcuro